Biogen Inc. says it has a drug to slow the progression of early-stage Alzheimer’s. But some researchers don’t think it’s the magic bullet we’ve been waiting for. (Getty Images)

Biogen Inc. says it has a drug to slow the progression of early-stage Alzheimer’s. But some researchers don’t think it’s the magic bullet we’ve been waiting for. (Getty Images)

New Alzheimer’s drug: Hope or Hype?

Company says its drug can slow the progression of the disease in its early stages.

It was news many people have been desperately hoping for — a new drug to slow the progression of early-stage Alzheimer’s disease.

The recent announcement from the company Biogen Inc. quickly spread across social media. The company’s stock price surged.

The intense interest in the announcement is underscored by the number of people affected by the disease.

Alzheimer’s ranks as the fourth leading cause of death in Snohomish County, taking the lives of 375 people last year. Some 110,000 people in Washington are living with the disease. That number is expected to jump 27 percent — to 140,000 — by 2025, according to an Alzheimer’s Association report.

But as with any announcement regarding a new medication, the question is, how much of the interest in what is being characterized as a potentially important new Alzheimer’s drug is hope versus hype?

In part, that’s because Biogen announced in March that it was discontinuing tests of the drug when initial analysis showed it wasn’t that effective.

Last month, the company reversed course, saying that a closer analysis of people using high doses of the drug showed it could slow cognitive decline among people with early-stage Alzheimer’s.

The company is seeking federal approval from the Food and Drug Administration to allow patients to be treated with the medication.

“I think it gives people hope,” said Carrie McBride, spokeswoman for the Washington state chapter of the Alzheimer’s Association. “It’s been about 15 years since a drug like this has been submitted to the FDA for approval.”

The drugs now on the market have had only moderate effectiveness, showing results only in some people and only for a short time, she said.

Federal approval to allow patients to be treated with the new drug also could open the door for other, more advanced therapies, she said. “This is really good news overall in the scientific and research communities,” McBride said.

Others, though, are raising questions about just how much benefit patients would receive.

A biotech podcast by STAT, a media company affiliated with the Boston Globe that covers health, medicine and scientific advances, said that it’s unclear if the FDA will approve the company’s request or ask for more tests to measure its effectiveness.

Journalist Sharon Begley noted in the podcast that it generally takes three years for Alzheimer’s to progress from a mild to moderate disease. “This would extend that to four years,” she said.

Biogen’s drug, called Aducanumab, is aimed at helping the body clear harmful plaques from the brain.

Dr. Eric Larson, a senior investigator at Kaiser Permanente Washington Health Research Institute, said that Biogen’s announcement is controversial among experts studying Alzheimer’s disease.

That’s in part because it’s very unusual for a drug to go forward after a test has failed, he said. “This is a condition that everybody hopes for — a single drug, a magic bullet,” Larson said.

Alzheimer’s is a complicated disease, caused by more than one problem, Larson said.

The plaques in the brain — which the Biogen drug seeks to attack — disrupts the functioning of neurons, the brain’s messenger service.

But there are three other problems that occur in the brain also associated with the disease, he said.

The upside to the years of attention on finding treatments for Alzheimer’s is that far more money is being spent on research, he said.

“How likely is it that a single drug will do what we want it to do — which is make it go away? I’m skeptical that this single drug will turn the tide,” Larson said. “But I sure hope there’s something like that someday.”

The Associated Press contributed to this report.

Sharon Salyer: 425-339-3486 or salyer@heraldnet.com.

Alzheimer’s information

The state chapter of the Alzheimer’s Association is at 19031 33rd Ave. W. No. 301, Lynnwood. Call 206-363-5500 or go to www.alz.org/alzwa for more information. Or contact the organization’s 24-hour helpline at 800-272-3900.

Talk to us

More in Life

See 81 original paintings by Jack Dorsey in the "No. 81" exhibit through May at Sunnyshore Studio on Camano Island.
Camano Island studio celebrates a patriarch of the arts

“No. 81” features 81 of Jack Dorsey’s paintings on his 81st birthday. You can see 28 of them at Sunnyshore Studio.

If you decide to add raised beds to your garden, the dimensions should be at least 10 to 12 inches high and no more than 4 to 5 feet wide. The length is up to you and your available space. (Nicole Phillips)
The benefits of vegetable (or flower) gardening with raised beds

Here’s what you need to know to build, plant and care for raised beds so that you can reap all the rewards.

The vocal supergroup Säje will perform at the DeMiero Jazz Festival, which is March 4-6 this year.
DeMiero Jazz Festival packed with headlining performers

Edmonds’ 45th annual event will feature 17 virtual performances, plus jazz workshops for local students.

Owners Kim and Larry Harris at Bayernmoor Cellars on Monday, Dec. 21, 2020 in Stanwood, Washington.  (Andy Bronson / The Herald)
World-class wine, from grapes grown right here

Bayernmoor Cellars makes award-winning pinot noir from grapes grown at its vineyard northeast of Stanwood.

About a dozen metal dinosaurs sit in the front yard of a home owned by Burt Mason and Mary Saltwick on Wednesday, Feb. 3, 2021 in Freeland, Washington. The couple are used to finding strangers in their yard and taking photos. Every year on their trip to Tucson, Burt and Mary bring home another figure  (Andy Bronson / The Herald)
Dinos on Whidbey? This Freeland yard is a Jurassic Park

These creatures from long ago won’t chomp or chase you, and you’re welcome to visit.

Drink This: 5 Snohomish breweries to host Smash and Dash

Each brewery takes the same base IPA recipe and then dry hops the beer with a different hop. Try them all.

Golden shakshuka

Gretchen McKay/Pittsburgh Post-Gazette
Golden Shakshuka is just the thing for a weekend brunch

This easy Middle Eastern egg dish is made with yellow bell peppers and yellow cherry tomatoes.

Don Sarver, left, and Kyle James, right, snowshoe on the Skyline Lake Trail on Saturday, Jan. 26, 2019 in Leavenworth, Wa. (Olivia Vanni / The Herald)
Avoiding avalanches: How to know and where to go

Follow these tips for researching on-the-ground conditions from comfort of your home or local library.

(Getty Images)
You voted: The best Chinese food in Snohomish County

Even during a pandemic, people still have their favorites.

Most Read